Supernus Pharma Director Files Intent to Sell $1.2M in Stock
SUPERNUS PHARMACEUTICALS, INC.
Subscribe to track SUPN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Supernus Pharma Director Files Intent to Sell $1.2M in Stock
Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN) Form: 144 | Filed: 2025-10-09 Significance: Medium
Insider: CHARLES NEWHALL Title: Director | Relationship: Director
Transaction (Proposed): • Type: Proposed Sale • Shares: 25,000 • Approx. Price: $48.00 • Value: $1,200,000 • Owned After: Not Disclosed
Key Insight: A Director has filed a notice of intent to sell $1.2M worth of stock. This sale is part of a pre-arranged 10b5-1 trading plan adopted in March 2025, which mitigates concerns of opportunistic selling.
Market Context: This filing follows several other sales by the same insider in August 2025 under the same 10b5-1 plan, indicating a consistent, planned liquidation schedule.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Executive Summary
- Trading Significance: Medium
- Key Takeaway: A Director at Supernus Pharmaceuticals, Charles Newhall, has filed a Form 144 indicating an intent to sell 25,000 shares of common stock valued at approximately $1.2 million.
- Market Impact: The sale is being conducted under a pre-established 10b5-1 trading plan, which typically lessens the immediate market impact as it signals a planned liquidation rather than a reaction to non-public information. However, the size of the sale may still attract attention.
Company Information
| Field | Value |
|---|---|
| Company | SUPERNUS PHARMACEUTICALS, INC. |
| Ticker Symbol | SUPN (Note: Not explicitly in filing, but commonly known) |
| CIK | 0001356576 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | CHARLES NEWHALL |
| CIK | 0001005544 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 (Notice of Proposed Sale) |
| Transaction Date | Approx. 2025-10-09 |
| Transaction Code | Not Applicable (Proposed Sale) |
| Security Type | Common Stock |
| Shares Involved | 25,000 |
| Price Per Share | Approx. $48.00 (Calculated from aggregate value) |
| Total Value | $1,200,000 |
| Shares Owned After | Not Disclosed |
| Ownership Type | Not Disclosed |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral to Slightly Negative
- Reasoning: Insider sales are often viewed as a bearish signal. However, the existence of a 10b5-1 plan, adopted on March 3, 2025, significantly mitigates this concern. The market may interpret this as a planned diversification or liquidity event for the insider rather than a lack of confidence in the company's future. The size of the sale is notable but not extreme relative to the company's market cap.
Volume & Sentiment
- Expected Volume Impact: A minor increase in trading volume may occur around the sale date as the 25,000-share block is absorbed by the market.
- Sentiment Indicator: Neutral. The 10b5-1 plan context neutralizes what would otherwise be a bearish signal.
Investment Insights
Positive Market Indicators
- The sale is part of a pre-arranged trading plan, reducing the likelihood that it is based on negative material non-public information.
Risk Factors
- A consistent pattern of selling by an insider, even if planned, can create a supply overhang on the stock.
- This filing follows several other sales by the same insider in the prior quarter, totaling over 6,000 shares for ~$270k, indicating a continued reduction of their holdings.
Key Takeaways
- Planned Liquidation: This is a planned sale under a 10b5-1 plan, not a spontaneous decision.
- Significant Value: The $1.2 million value of the proposed sale is substantial and represents a significant liquidation for the insider.
- Pattern of Selling: This transaction is part of an ongoing series of sales by Director Charles Newhall, suggesting a long-term strategy to reduce his position in the company.
Contextual Analysis
Timing Significance
The filing date of October 9, 2025, does not appear to coincide with any immediate major corporate announcements. The sale is planned to occur around this date, following the end of the third quarter.
Transaction Context
The filing explicitly notes a 10b5-1 plan adoption date of March 3, 2025. It also discloses three sales that occurred in August 2025 under the same plan, reinforcing the pre-planned nature of this activity. This transparency is crucial for market interpretation.
Company Context
Supernus Pharmaceuticals operates in the pharmaceutical industry. Analysis of this filing should be paired with an understanding of the company's drug pipeline, recent clinical trial results, and upcoming regulatory milestones. This insider sale, being planned, is unlikely to be directly tied to a very recent, unknown event.
Risk Assessment
Risk Level: Low
Risk Factors
- Perception Risk: Even planned sales can be perceived negatively by retail investors who may not understand the nuances of 10b5-1 plans.
- Supply Overhang: Continued, regular sales from insiders can put downward pressure on the stock price over time.
Market Considerations
- Plan Details: The market does not know the full parameters of the 10b5-1 plan (e.g., total shares to be sold, price targets, duration).
- Sector Trends: The broader performance of the biotechnology and pharmaceutical sectors will likely have a greater impact on the stock price than this single planned transaction.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-09 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.